# New Targeted Alpha Therapy Shows Promise for Advanced Neuroendocrine Tumors: What Patients Need to Know

Neuroendocrine tumors (NETs) can be notoriously difficult to treat once they spread, but a new type of targeted radiation therapy shows remarkable promise. This meta-analysis of five clinical studies involving 153 patients found that 225Ac-DOTATATE — a treatment that attaches radioactive actinium-225 to a molecule that targets tumor cells — achieved disease control in 88% of patients with advanced NETs, with a remarkably low rate of serious side effects. Even more encouraging, the treatment worked in 51% of patients who had already failed a standard earlier therapy called 177Lu-PRRT, suggesting this approach could be a powerful second-line option for some of the hardest-to-treat cases.

# New Targeted Alpha Therapy Shows Promise for Advanced Neuroendocrine Tumors: What Patients Need to Know

## Table of Contents

- Key Points
- Background: Understanding Neuroendocrine Tumors and Current Treatments
- Study Methods: How This Research Was Conducted
- Key Findings: Response Rates, Disease Control, and Safety
- Subgroup Analysis: Patients Who Had Prior 177Lu-PRRT Therapy
- Toxicity Profile: Understanding the Side Effects
- Clinical Implications: What This Means for Patients
- Study Limitations: What This Research Couldn't Prove
- Recommendations: What Patients Should Consider
- Frequently Asked Questions
- Source Information

## Key Points

- In a meta-analysis of 5 studies with 153 patients, 225Ac-DOTATATE achieved a 52% disease response rate and 88% disease control rate in advanced neuroendocrine tumors.
- Among 89 patients who had failed 177Lu-PRRT, 51% responded to 225Ac-DOTATATE, offering a potential second-line option when standard therapy has stopped working.
- Hematological toxicity was only 2%, kidney toxicity occurred in 2 patients, and no liver or high-grade adverse events were reported; temporary nausea from amino acid infusion was common.
- This treatment uses alpha particles (actinium-225) that cause severe DNA damage in tumor cells, which may overcome resistance to beta-particle therapy like 177Lu-DOTATATE.
- Caution is needed since results come from small, non-randomized case series without long-term survival data, and confirmatory prospective multicenter trials are still necessary.

## Background: Understanding Neuroendocrine Tumors and Current Treatments

Neuroendocrine tumors (NETs) are a diverse group of cancers that arise from neuroendocrine cells — specialized cells that share characteristics of both nerve cells and hormone-producing endocrine cells. These tumors most commonly develop in the gastrointestinal tract, pancreas, and stomach, although they can appear elsewhere in the body.

The incidence of NETs has been steadily climbing in recent years. This rise is partly due to improved diagnostic techniques that detect these often slow-growing tumors earlier than before.

Traditional treatment approaches for NETs typically include:

-
**Surgery** to remove the tumor when possible
-
**Endocrine therapy** (hormone-based treatments such as somatostatin analogs)
- **Targeted chemotherapeutic agents**
-
**Radiochemotherapy** (combining radiation with chemotherapy)

Despite progress in diagnosis and treatment, therapeutic options remain limited for patients with advanced or metastatic disease. Their prognosis is generally poor, highlighting an urgent need for new treatment strategies.

### What is Peptide Receptor Radionuclide Therapy (PRRT)?

Peptide receptor radionuclide therapy (**PRRT**) is a type of targeted radiation therapy that has garnered significant research attention in recent years. The approach works by attaching a radioactive isotope to a molecule that specifically binds to somatostatin receptors (SSTRs), which are often overexpressed on the surface of NET cells. This allows radiation to be delivered precisely to tumor cells while largely sparing healthy tissue.

The most widely applied form of PRRT uses 177Lu-DOTATATE, which employs a beta-emitting radionuclide (lutetium-177). This treatment received Food and Drug Administration (FDA) approval in 2018 for metastatic NETs.

However, studies have revealed a significant problem: even patients with high somatostatin receptor expression who initially respond well to 177Lu-DOTATATE eventually develop resistance to this beta-emitting PRRT, resulting in disease progression. This resistance has driven researchers to explore alternative radiation sources.

### Enter Targeted Alpha Therapy with Actinium-225

**Targeted alpha therapy (TAT)** has emerged as a promising alternative to beta-emitting radionuclides. The most widely studied alpha-emitting radionuclide is actinium-225 (225Ac). Compared to 177Lu, 225Ac offers several distinct physical advantages:

-
**Half-life of 9.9 days**, allowing sufficient time for the drug to reach and accumulate in tumors
-
**High energy output** (5.8–8.4 MeV), delivering a much more potent dose of radiation to cancer cells
-
**Short range** (47–85 micrometers), meaning its destructive effect is confined to a very small area around the tumor cell
-
**High linear energy transfer (LET)** of approximately 100 keV/mm — roughly 100 times higher than beta particles — making it exceptionally effective at causing irreparable DNA damage to cancer cells

These properties allow 225Ac-DOTATATE to deliver powerful tumor-killing effects with relatively minimal damage to surrounding normal tissues. Preliminary studies have suggested that 225Ac-DOTATATE offers superior potential for targeting NETs, making it a promising alternative to 177Lu-based therapies.

However, clinical research on 225Ac-DOTATATE for NETs has remained limited, with small sample sizes and inconsistent findings across studies. This meta-analysis was designed to systematically evaluate the safety and efficacy of 225Ac-DOTATATE, pooling together the available worldwide data to provide more robust evidence for clinical practice.

## Study Methods: How This Research Was Conducted

### Systematic Review Design and Registration

This systematic review followed the **Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)** guidelines — an internationally recognized set of standards designed to ensure transparency and completeness in systematic reviews. The study protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO) under registration number **CRD42025633806**.

### Literature Search Strategy

The researchers conducted a comprehensive systematic search of two major medical databases — PubMed and Embase — covering all records from each database's establishment through **December 15, 2024**. The search strategy combined keywords related to the treatment ("225Ac-DOTATATAE") with terms for the disease ("neuroendocrine tumor," "neuroendocrine tumour," "neuroendocrine neoplasm," "neuroendocrine cancer," and "neuroendocrine carcinoma").

Two independent researchers screened the literature and extracted data, reaching consensus through unanimous agreement. In cases of disagreement, a third-party researcher was consulted to resolve discrepancies.

### Inclusion and Exclusion Criteria

To be included in this meta-analysis, studies had to meet all of the following criteria:

1.
**Confirmed NET diagnosis** through biopsy, laboratory examination, and imaging examination
1.
**Advanced disease** — patients with incomplete or unresectable tumors, postoperative disease recurrence, or distant metastases
1.
**Visible tumor receptor expression** — baseline 68Ga-DOTATATE/DOTANOC PET/CT scans had to show high somatostatin receptor (SSTR) expression, defined as uptake greater than that of the normal liver

Patients could be treatment-naive or resistant to conventional therapies or 177Lu-PRRT. Studies involving animal experiments, cell studies, reviews, meta-analyses, replications, case reports, or letters were excluded.

### Quality Assessment

The quality of the five included studies was assessed using the **JBI Critical Appraisal Checklist for Case Series**, a validated tool that evaluates 10 key criteria including clear inclusion criteria, standard and reliable condition measurement, valid identification methods, consecutive participant inclusion, complete participant inclusion, clear reporting of demographics and clinical information, clearly reported outcomes, and appropriate statistical analysis.

While all five studies were deemed eligible for inclusion, the assessment identified a few minor issues. In the Ballal 2022 study, it was unclear whether participants were consecutively included. None of the studies clearly reported demographic information about the presenting sites or clinics. These issues represent minor quality concerns that are common in case series research.

### Data Extraction and Outcome Measures

The researchers extracted detailed data from each study, including:

- Basic characteristics: first author, publication time, treatment response criteria, patient numbers, gender distribution, primary tumor type, Ki-67 index (a measure of tumor cell growth speed), prior treatments, and metastatic sites
- Treatment details: dose per cycle, total cycles, interval between cycles, follow-up time, and cumulative activity
- Therapeutic outcomes: disease response rates (DRRs) and disease control rates (DCRs)

The primary measure of efficacy was the **disease response rate (DRR)**, which represents the percentage of patients achieving either a complete response (CR — no detectable tumor) or partial response (PR — significant tumor shrinkage). The **disease control rate (DCR)** was defined as the percentage of patients achieving CR + PR + stable disease (SD — tumor neither shrinking nor growing significantly).

Tumor responses were assessed using **Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)** in four studies, which uses conventional imaging (CT or MRI) measurements. One study used **PET Response Evaluation Criteria in Solid Tumors 1.0 (PERCIST 1.0)**, which incorporates metabolic tumor activity seen on PET scans.

Toxicity was collected and graded according to the **Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0)**, a standardized system used to describe the severity of treatment side effects, with Grade I being mild and Grade IV being life-threatening.

### Statistical Analysis

All statistical analysis was performed using Stata version 16.0. Forest plots were generated to visualize and pool the DRR and DCR data from individual studies.

The degree of heterogeneity (variability) between studies was assessed using the I² statistic:

- If I² ≤ 50% and p < 0.10 (no significant heterogeneity), a fixed-effects model was used
- If I² > 50% and p ≥ 0.10 (significant heterogeneity), a random-effects model was used

Subgroup analyses were conducted to examine whether patients who had previously received 177Lu-PRRT responded differently to 225Ac-DOTATATE than patients who had never received this prior treatment. Funnel plots and Egger's test were used to assess publication bias, with a p-value of less than 0.05 considered statistically significant.

## Key Findings: Response Rates, Disease Control, and Safety

### Study Selection and Patient Population

The initial literature search identified **104 records**. After excluding 34 duplicate records and 30 articles that did not meet criteria based on title and abstract review, the full texts of the remaining articles were examined. Ultimately, five studies met all inclusion criteria and were included in the meta-analysis.

These five studies involved a total of **153 patients**. The tumor types represented included:

-
**Paraganglioma (PGL)** — rare tumors that arise from nerve tissue
-
**Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)** — the most common type, arising in the digestive system and pancreas
-
**Adrenal gland pheochromocytoma** — tumors of the adrenal medulla
- Medullary thyroid carcinoma, lung carcinoid, tonsillar NET, and other tumor types

Treatment protocols across the studies were broadly similar: patients received a dose of **100–120 kBq/kg of 225Ac-DOTATATE per treatment cycle**, with the number of cycles ranging from 1 to 9 (median 1–4 depending on the study), and treatment intervals of approximately 8 weeks between cycles.

### Overall Response Rates

All five studies reported treatment responses. The pooled results revealed the following:

-
**Disease response rate (DRR): 52%** (95% confidence interval: 43%–61%). This means that roughly half of all patients experienced significant tumor shrinkage or complete disappearance of their tumors. A fixed-effects model was used (I² = 0.00%, p = 0.78), indicating very low heterogeneity — the studies were highly consistent with one another.
-
**Disease control rate (DCR): 88%** (95% confidence interval: 81%–94%). This means that nearly 9 out of 10 patients achieved either tumor shrinkage or disease stability — no further tumor growth. A random-effects model was used due to moderate heterogeneity (I² = 62.89%, p = 0.03).

These numbers are particularly striking when compared with historical data. Published meta-analyses on 177Lu-PRRT reported DRRs ranging from approximately **20% to 35%**. The 52% DRR observed with 225Ac-DOTATATE represents a substantial improvement over beta-based therapy.

Even more compelling is the comparison with the landmark NETTER-1 and NETTER-2 clinical trials: patients who had not previously received 177Lu-PRRT and directly received 225Ac treatment achieved a DRR of **47%**, which is higher than the **18%** observed in the NETTER-1 trial and the **43%** observed in the NETTER-2 trial for patients treated with 177Lu-DOTATATE. The NETTER trials were the pivotal studies that led to 177Lu-DOTATATE's FDA approval.

## Subgroup Analysis: Patients Who Had Prior 177Lu-PRRT Therapy

One of the most clinically important questions this meta-analysis sought to answer was whether 225Ac-DOTATATE could help patients who had already failed 177Lu-PRRT therapy. This is a critical issue because many patients with advanced NETs will eventually progress on standard PRRT, and treatment options for these patients are extremely limited.

### Patients Previously Treated with 177Lu-PRRT

Four studies reported data on **89 patients** who had received 177Lu-PRRT before starting 225Ac-DOTATATE. These patients either chose 225Ac-DOTATATE due to disease progression after 177Lu treatment or had to discontinue 177Lu after reaching the maximum cumulative tolerated dose.

The results in this difficult-to-treat group were encouraging:

-
**DRR: 51%** (95% CI: 35%–66%), calculated using a fixed-effects model (I² = 35.49%, p = 0.2)
-
**DCR: 90%** (95% CI: 69%–100%), calculated using a random-effects model (I² = 73.37%, p = 0.01)

In other words, more than half of patients who had already failed standard beta-particle PRRT experienced significant tumor shrinkage when switched to alpha-particle therapy with 225Ac-DOTATATE.

### Patients Who Were 177Lu-PRRT Naive

Data from three studies on patients who had never received 177Lu-PRRT showed:

-
**DRR: 47%** (95% CI: 1%–97%), using a random-effects model (I² = 75.99%, p = 0.02). The wide confidence interval reflects the small number of patients in this subgroup.
-
**DCR: 89%** (95% CI: 72%–100%), using a fixed-effects model (I² = 0.00%, p = 0.77).

Interestingly, patients who had previously received 177Lu-PRRT had slightly higher DRRs (51% vs. 47%) and DCRs (90% vs. 89%) compared to treatment-naive patients. The researchers caution, however, that these differences should be interpreted carefully given the small sample sizes involved.

The survival of these treatment effects in the face of prior beta-therapy resistance may be explained by the fundamental biological differences between beta and alpha particles. Beta particles emitted by 177Lu have relatively low energy and a wide range of action, factors that can contribute to the development of resistance in tumor cells. Potential resistance mechanisms include the downregulation of somatostatin receptor expression on tumor cells, enhanced DNA repair mechanisms within tumor cells, and changes in the tumor microenvironment.

In contrast, alpha particles like those emitted by 225Ac have an extremely high linear energy transfer (~100 keV/mm). They induce **DNA double-strand breaks (DSBs)** — the most lethal form of DNA damage — that are typically very difficult for cancer cells to repair. Furthermore, alpha particles demonstrate strong cytotoxic effects even against resistant tumor cells in a low proliferative state (meaning they can kill cancer cells that are dividing slowly, which often resist conventional chemotherapy). This mechanism explains why 225Ac-DOTATATE has shown significant potential in overcoming resistance to 177Lu-PRRT.

## Toxicity Profile: Understanding the Side Effects

A major concern with any new cancer therapy is its safety profile. The meta-analysis carefully examined treatment-related toxicities across all five studies, categorizing side effects by organ system and severity according to CTCAE 5.0.

### Hematological (Blood) Toxicity

Hematological toxicity — damage to blood cells — was observed in four studies and affected just **7 patients**. The pooled proportion of hematological toxicity was remarkably low at **2%** (95% CI: 0.00%–5%), calculated using a fixed-effects model (I² = 0.00%, p = 0.07).

The specific blood-related side effects reported included:

-
**Anemia** (low red blood cell count): Grade I in 3 patients (Yang 2024 study), Grade II in 1 patient (Demirci 2023 study)
-
**Leukopenia** (low white blood cell count): Grade I in 2 patients (Ballal 2019 and Yang 2024 studies), Grade II in 1 patient (Demirci 2023 study)
-
**Thrombocytopenia** (low platelet count): Grade III in 1 patient (Ballal 2022 study). Grade III thrombocytopenia is considered a serious but manageable complication that requires medical attention but is not immediately life-threatening.

Notably, **no Grade III or IV hematological toxicity** was observed in six patients, meaning the vast majority of blood-related side effects were mild (Grade I or II), temporary, and did not require discontinuation of treatment.

### Kidney (Renal) Toxicity

The kidneys are a major concern in all forms of PRRT because the radiopeptides are cleared through the renal system and can accumulate in kidney tissue. In this meta-analysis, only **2 patients** experienced renal toxicity, and in both cases it was mild:

- Grade I nephrotoxicity in 1 patient (Ballal 2019 study)
- Grade II nephrotoxicity in 1 patient (Demirci 2023 study)

No Grade III or IV renal toxicity was observed in any patient. Importantly, all studies used **amino acid infusions** to protect the kidneys during treatment — a standard protective measure that helps prevent the radioactive peptide from being retained in kidney tissue. The two cases of renal toxicity were likely temporary effects.

### Liver (Hepatic) Toxicity

No hepatotoxicity was reported in any of the studies during the follow-up period. This is reassuring, as the liver is another common site of radiation accumulation in patients with liver metastases.

### Other Reported Side Effects

Four studies reported transient symptoms such as **nausea, vomiting, and diarrhea** during the treatment process, which were attributed to the amino acid infusion used for kidney protection. These symptoms resolved after the treatment session was completed and did not represent a lasting problem for patients.

One additional case worth noting: Kavanal et al., though not part of this meta-analysis, reported a case of subclinical hypothyroidism (mildly underactive thyroid, detectable only by blood test) after 225Ac-DOTATATE treatment in a patient with metastatic NETs. No similar findings were observed in the studies included in this analysis.

### Treatment Tolerance and Quality of Life

The average cumulative activity (total amount of radioactivity administered) ranged from **7.5 to 86.6 MBq**, and the longest follow-up period reached **41 months**. During follow-up, patients exhibited good overall tolerance to the treatment.

Importantly, four studies that tracked patient-reported outcomes demonstrated **significant improvements in physical function, emotional state, and social functioning** following treatment with 225Ac-DOTATATE. The researchers noted that as a salvage therapy (treatment given after other therapies have failed), 225Ac-DOTATATE has shown remarkable potential in improving the quality of life and clinical symptoms of patients with NETs.

One cautionary note: the researchers emphasize that while higher-grade adverse events were uncommon, transient, or unlikely to be directly treatment-related, further research is still needed to accurately measure the absorbed radiation doses in target and non-target organs. The maximum tolerated dose of alpha therapy remains an open question that requires careful study.

## Clinical Implications: What This Means for Patients

The findings of this meta-analysis carry substantial weight for patients with advanced NETs and the oncologists who treat them. Here are the key takeaways:

1.
**A new option after treatment failure.** Patients who have progressed on 177Lu-DOTATATE — the current standard of care for metastatic NETs — have very limited options. This analysis suggests 225Ac-DOTATATE can achieve meaningful tumor response in more than half of these patients, offering genuine hope in a situation where treatment choices were previously scarce.
1.
**Improved response compared to beta therapy.** The 52% DRR observed with 225Ac-DOTATATE substantially exceeds the 20%–35% DRRs historically reported for 177Lu-based PRRT. Even patients receiving 225Ac-DOTATATE as their first PRRT (47% DRR) appear to respond better than patients receiving 177Lu-DOTATATE in the pivotal NETTER trials (18%–43% DRR).
1.
**Remarkable safety profile.** With only 2% hematological toxicity, 2 cases of mild kidney toxicity, and no liver toxicity or Grade III/IV events, the safety profile of 225Ac-DOTATATE appears favorable compared to chemotherapy agents commonly used in this setting. The short-range nature of alpha particles, which limits damage to surrounding healthy tissue, likely underlies this safety advantage.
1.
**Quality of life improvements.** Multiple studies reported improvements in patients' physical, emotional, and social functioning after treatment — an important consideration for patients facing a chronic, advanced cancer diagnosis.
1.
**No publication bias detected.** Statistical testing (funnel plots and Egger's test) found no evidence of publication bias, meaning the findings are unlikely to be distorted through selective reporting of positive results.

## Study Limitations: What This Research Couldn't Prove

While these results are encouraging, the researchers were transparent about the limitations of their analysis, and patients should understand these caveats:

-
**Small sample sizes.** The meta-analysis was based on only five studies involving 153 patients. The subgroup analyses were based on even smaller numbers — for example, only three studies contributed data on 177Lu-naive patients, resulting in very wide confidence intervals (DRR range: 1%–97%). This limits the robustness of the conclusions.
-
**Differences in patient demographics.** There were differences in the demographic characteristics of patients across the included studies, including variations in primary tumor type, Ki-67 index (tumor aggressiveness marker), and prior treatment histories.
-
**No long-term outcomes data.** Because of limited available data, this analysis could not explore long-term prognostic outcomes such as **overall survival (OS)** — how long patients lived — or **progression-free survival (PFS)** — how long patients remained without disease progression. These are critical endpoints that future research must address.
-
**Study design limitations.** All included studies were case series, which lack the rigor of randomized controlled trials (RCTs). There were no control groups for comparison.
-
**Heterogeneity in some analyses.** The DCR analysis showed moderate heterogeneity (I² = 62.89%), and the subgroup analyses for 177Lu-pretreated patients (I² = 73.37%) and naive patients (I² = 75.99%) showed even higher heterogeneity, suggesting the results should be interpreted with caution.

The researchers explicitly describe this as a **"preliminary summary"** and emphasize that because of the limited number of participants, the conclusions drawn still lack full robustness.

## Recommendations: What Patients Should Consider

Based on this meta-analysis and its findings, patients and healthcare providers should keep the following points in mind:

1.
**Discuss this treatment with your oncology team.** If you have advanced or metastatic NETs and have progressed on 177Lu-DOTATATE therapy, 225Ac-DOTATATE may be an appropriate next option. Ask your oncologist whether referral to a nuclear medicine center that offers this treatment is appropriate for your specific case.
1.
**Not all patients will be eligible.** Patients must have high somatostatin receptor expression on PET/CT imaging (uptake greater than the liver) to be candidates. Your doctor will need to confirm this with an appropriate scan.
1.
**Expect kidney protection measures.** All studies in this analysis used amino acid infusions to protect the kidneys during treatment. Some temporary nausea, vomiting, or diarrhea during infusions is common but typically resolves after treatment is complete.
1.
**Understand the treatment schedule.** In the studies reviewed, treatment was given every 8 weeks, typically for 3–4 cycles. Cumulative radiation activity ranged from approximately 8 to 87 MBq depending on the study and individual patient factors.
1.
**Recognize the need for more research.** The researchers call for high-quality, prospective, multicenter randomized controlled trials to further clarify the optimal therapeutic dosage of 225Ac-DOTATATE and to explore combination treatment strategies in advanced metastatic NETs. Patients considering this treatment should ideally do so in the context of a clinical trial or at a center with substantial experience in alpha-particle therapy.
1.
**Balance hope with realism.** While 52% of patients responded to treatment, that also means 48% did not. However, the 88% disease control rate indicates that almost all patients derived some benefit, whether from tumor shrinkage or stabilization of their disease.

## Frequently Asked Questions

### What is 225Ac-DOTATATE and how does it work for neuroendocrine tumors?

225Ac-DOTATATE is a targeted radiation therapy that attaches radioactive actinium-225 to a molecule that binds to somatostatin receptors on neuroendocrine tumor cells. Unlike standard beta-particle therapy, it uses alpha particles, which deliver a more powerful, short-range radiation dose that causes difficult-to-repair DNA damage in cancer cells while sparing healthy tissue.

### How well did 225Ac-DOTATATE work in advanced neuroendocrine tumors in this analysis?

In this meta-analysis of five studies involving 153 patients with advanced neuroendocrine tumors, 52% of patients had significant tumor shrinkage or complete disappearance (disease response rate), and 88% achieved either shrinkage or stable disease (disease control rate). These results were consistent across the studies.

### Can 225Ac-DOTATATE help patients who have already failed standard 177Lu-PRRT therapy?

Yes, in this analysis of 89 patients who had previously received 177Lu-PRRT and then progressed or reached dose limits, 51% responded to 225Ac-DOTATATE and 90% achieved disease control. This suggests it may be a powerful option for patients with very limited alternatives after standard PRRT fails.

### What side effects should I expect with 225Ac-DOTATATE treatment?

Serious side effects were uncommon in the five studies. Blood-related toxicity occurred in only about 2% of patients (mostly mild anemia or low white blood cells), kidney toxicity was seen in only 2 patients (mild), and no liver toxicity or severe Grade III/IV events were reported. Temporary nausea, vomiting, or diarrhea during infusions were common and resolved afterward.

### What is the treatment schedule and how long does it take?

In the studies reviewed, patients received a dose of 100–120 kBq/kg of 225Ac-DOTATATE per cycle, with treatment cycles repeated every 8 weeks. The number of cycles ranged from 1 to 9, with a median of 1–4 depending on the study. The average cumulative activity ranged from about 7.5 to 86.6 MBq, with follow-up up to 41 months.

### Am I eligible for 225Ac-DOTATATE treatment?

Eligibility requires a confirmed neuroendocrine tumor that is advanced or has spread, and a PET/CT scan showing high somatostatin receptor expression—tumor uptake greater than normal liver. This treatment can be considered for patients who are treatment-naive or who have not responded to other therapies, including 177Lu-PRRT. Your oncologist must confirm eligibility with appropriate imaging.

### What does this treatment offer in terms of quality of life?

Four studies tracked patient-reported outcomes and found significant improvements in physical function, emotional state, and social functioning after treatment with 225Ac-DOTATATE. The researchers noted that as a salvage therapy after other treatments have failed, this approach shows remarkable potential in improving clinical symptoms and quality of life, despite the need for more research.

### Should I get a second opinion about 225Ac-DOTATATE if my neuroendocrine tumor has progressed after 177Lu-PRRT?

A patient with advanced neuroendocrine tumors who has already progressed on 177Lu-DOTATATE may face limited options and should consider a second opinion to decide whether 225Ac-DOTATATE is worth pursuing. In pooled results from 153 patients, 225Ac-DOTATATE achieved disease control in 88% and tumor shrinkage in 52%; among those who had failed prior 177Lu-PRRT, 51% still responded. Side effects were mostly mild, with only 2% hematological toxicity. A second opinion can clarify whether your tumor shows high somatostatin receptor expression on PET/CT, since that determines eligibility. Diagnostic Detectives Network provides independent expert second opinions.

## Source Information

**Original article title:** The therapeutic efficacy of <sup>225</sup>Ac-DOTATATE in neuroendocrine tumors: a preliminary meta-analysis.

**Authors:** Ma J, Ji Y, Yao Z, Yangqing J, Zhang C.

**Affiliation:** Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China; Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province; Institute of Nuclear Medicine, Southwest Medical University

**Journal:** Frontiers in Oncology, Volume 15, Article 1696063

**Publication date:** October 31, 2025

**DOI:** 10.3389/fonc.2025.1696063

**Study registration:** PROSPERO identifier CRD42025633806

**Funding:** The authors declared that no financial support was received for the research and/or publication of this article.

**Conflicts of interest:** The authors declared no commercial or financial relationships that could be construed as a potential conflict of interest.

**Note:** This patient-friendly article is based on peer-reviewed research. It is intended for informational purposes and should not replace professional medical advice. Always consult with a qualified healthcare provider before making decisions about cancer treatment.


---
Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay.
Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact
Canonical page: https://diagnosticdetectives.com/products/new-targeted-alpha-therapy-shows-promise-for-advanced-neuroendocrine-tumors-what-patients-need-to-know